SR One, the venture capital arm of GlaxoSmithKline (NYSE: GSK) is the lead investor in a $21.7 million round of financing for f-star GmbH.

The biopharmaceutical firm is based in Austria.

SR One partner Deborah Harland joined the f-star board as part of the deal.

F-star GmbH focuses on antibody development.

“f-star has shown that its Modular Antibody Technology platform can generate multiple high affinity biotherapeutics against targets of varying precedence and novelty in both single- and bi-specific formats”, said Dr Harland in a statement. “We believe the platform has the potential to generate numerous novel differentiated biologics with advanced efficacy, tissue penetration and targeting capabilities compared to traditional antibodies and are excited to be part of the next stage of the company’s development.”

GSK employs some 5,000 people in the Triangle area.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.